Please login to the form below

brodalumab

This page shows the latest brodalumab news and features for those working in and with pharma, biotech and healthcare.

Sun Pharma passes milestone with novel psoriasis drug approval

IL-23-selective follow-up Tremfya (guselkumab) as well as three IL-17 inhibitors - Novartis’ Cosentyx (secukinumab), Eli Lilly’s Taltz (ixekizumab) and Valeant Pharma’s Siliq (brodalumab).

Latest news

AbbVie reports more solid data for would-be psoriasis blockbuster

ixekizumab) and Valeant’s Siliq (brodalumab).
Lilly claims another EU okay for Taltz

leader. A third IL-17 drug - Valeant’s Siliq (brodalumab) - was launched in the third quarter in the US at a discount to Cosentyx and Taltz but the company has yet
European Commission backs LEO Pharma’s Kyntheum

Novel biologic therapies such as brodalumab mean that achieving completely clear skin can now be a reality for people with moderate-to-severe psoriasis.”. ... Additionally, across all three trials, 56-61% of patients reported the skin condition no
Biosimilars eat into J&J's Remicade sales

brodalumab) - which claimed an earlier-than-expected FDA approval for psoriasis last week.
Payback time nears as Sanofi gets CHMP backing for biosimilar Humalog

Meanwhile among other positive opinions granted by the CHMP was one for Leo Pharma's interleukin-17 inhibitor Kyntheum (brodalumab) - acquired from AstraZeneca - for plaque psoriasis.

More from news
Approximately 9 fully matching, plus 32 partially matching documents found.

Latest Intelligence

Pharma deals in September 2015

Brodalumab is phase III complete, but is thought to have been cast off due to concerns raised over links to the drug and suicidal thoughts. ... Collaboration - discovery. 500. AstraZeneca. Valeant Pharmaceuticals. Brodalumab for psoriasis, ready for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Editorial Assistant – Greater Manchester: DOE

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Business Development Director – Health Education: excellent commission

Medical (Scientific) Director: £120, 000 benefits

Senior Account Manager: Competitive Salary Offered

Senior Developer with management potential, Healthcare Brand Com...: circa £50K

Medical Writer: Bonus Scheme, PTO &Private Healthcare

Experienced Medical Writers: Competitive Salary and Benefits

Editorial Manager - MedComms: DOE

Account Manager: Negotiable

Principal Health Economist - North-West: Negotiable

Account Manager / Senior Account Manager: 35, 000-40, 000

Manager - Immunology, Therapeutic Area Communications & Publ...: Competitive Salary Offered

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

SAE – Healthcare PR – Award-Winning Consultancy: Salary TBC

Account Manager / Account Director: Competative

Account Director: Competitive Salary Offered

Business Director: Competitive Salary Offered

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Account Manager- Healthcare Advertising: Negotiable

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Systematic Reviewer - Oxford: Negotiable

Account Manager – Creative Healthcare Advertising – Central Lond...: Salary TBC

Senior Account Executive with progression to Account Manager, Me...: Excellent package

Digital Communications Lead, Healthcare Brand and Medical Commun...: up to £50K

Subscribe to our email news alerts

PMHub

Add my company

Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today: Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham: Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone: Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...